Table 1. Associations between FGFR2 positivity and clinicopathological factors in EGJ adenocarcinoma patients with tumor resection.
| FGFR2 amplification | FGFR2 IHC | |||||
|---|---|---|---|---|---|---|
| Negative | Positive | P value | Negative | Positive | P value | |
| No. patients (%) | 119 (85%) | 21 (15%) | 68 (39%) | 108 (61%) | ||
| Age | 0.971 | 0.520 | ||||
| Mean ± SD | 68 ± 12 | 67 ± 12 | 67 ± 11 | 69 ± 12 | ||
| Sex | 1.000 | 0.308 | ||||
| Male | 96 (81%) | 17 (81%) | 51 (75%) | 88 (81%) | ||
| Female | 23 (19%) | 4 (19%) | 17 (25%) | 20 (19%) | ||
| Siewert classification | 0.945 | 0.025 | ||||
| I | 20 (17%) | 4 (19%) | 5 (7%) | 24 (22%) | ||
| II | 25 (21%) | 4 (19%) | 18 (27%) | 23 (21%) | ||
| III | 74 (62%) | 13 (62%) | 45 (66%) | 61 (57%) | ||
| Tumor depth | 0.689 | < 0.001 | ||||
| T1 | 37 (31%) | 6 (29%) | 42 (62%) | 23 (21%) | ||
| T2 | 19 (16%) | 2 (9%) | 13 (19%) | 10 (9%) | ||
| T3 | 46 (39%) | 8 (38%) | 9 (13%) | 52 (48%) | ||
| T4 | 17 (14%) | 5 (24%) | 4 (6%) | 23 (22%) | ||
| Tumor size (mm) | 0.919 | 0.110 | ||||
| Mean ± SD | 54 ± 7 | 56 ± 16 | 45 ± 10 | 67 ± 8 | ||
| Lymph node metastasis | 0.286 | < 0.001 | ||||
| Negative | 66 (55%) | 9 (43%) | 53 (78%) | 49 (45%) | ||
| Positive | 53 (45%) | 12 (57%) | 15 (22%) | 59 (55%) | ||
| Distant metastasis | 0.990 | 0.030 | ||||
| Negative | 108 (91%) | 19 (90%) | 66 (97%) | 94 (87%) | ||
| Positive | 11 (9%) | 2 (10%) | 2 (3%) | 14 (13%) | ||
| Histopathological types | 0.305 | 0.235 | ||||
| Well-moderate | 80 (67%) | 17 (81%) | 52 (76%) | 73 (68%) | ||
| Poorly | 39 (33%) | 4 (19%) | 16 (24%) | 35 (32%) | ||
In multiple-hypothesis testing, the significant P value was adjusted to P = 0.05/16 = 0.003. Thus, a P value between 0.05 and 0.003 should be regarded as borderline significant.
EGJ, esophagogastric junction; FGFR2, fibroblast growth factor receptor 2; IHC, immunohistochemistry; SD, standard deviation. N = 176.